Report describes first successful practical synthesis of AMF-26 anti-cancer substance

NewsGuard 100/100 Score

Scientists are reporting development of the first practical way to make large amounts of a promising new anti-cancer substance that kills cancer cells differently than existing medicines. Their article on synthesis of the substance, and tests demonstrating its effectiveness in the laboratory, appears in ACS' Journal of Medicinal Chemistry.

Isamu Shiina and colleagues explain that the substance, AMF-26, showed promise against certain forms of cancer in laboratory studies, fostering excitement about its potential for development as a new anti-cancer drug. That excitement centered on AMF-26's action in targeting a structure in cells, the Golgi apparatus, that had never been exploited in the past. The Golgi apparatus sorts and modifies hormones, enzymes and other key proteins for transport elsewhere.

However, AMF-26 had been available in only small amounts by semisynthesis starting from AMF-14, which was extracted from the common soil mold of the genus Trichoderma.

Their report describes the first successful practical synthesis of AMF-26 and laboratory tests showing that the synthetic AMF-26 is just as effective as its natural counterpart. "The large-scale production of AMF-26 and its derivatives for the development of novel anticancer drugs are now in progress in this laboratory," the report states.

Source: American Chemical Society

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Aspirin shows no benefit in preventing breast cancer recurrence, study finds